Hanan Goldberg1,2, Ardalan E Ahmad1, Thenappan Chandrasekar3, Laurence Klotz4, Mark Emberton5, Masoom A Haider6, Samir S Taneja7, Karan Arora8, Neil Fleshner1, Antonio Finelli1, Nathan Perlis1, Mark D Tyson8, Zachary Klaassen9,10, Christopher J D Wallis1. 1. Urology Division, Surgical Oncology Department, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada. 2. Urology Department, SUNY Upstate Medical University, Syracuse, New York. 3. Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 4. Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 5. Division of Surgery and Interventional Science, University College London, London, United Kingdom. 6. Department of Medical Imaging, Princess Margaret Cancer Center, Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, Ontario, Canada. 7. Department of Urology and Radiology, NYU Langone Health, New York, New York. 8. Department of Urology, Mayo Clinic, Phoenix, Arizona. 9. Division of Urology, Department of Surgery, Medical College of Georgia, Augusta University, Augusta, Georgia. 10. Georgia Cancer Center, Augusta, Georgia.
Abstract
PURPOSE: Multiparametric magnetic resonance imaging with informed targeted biopsies has changed the paradigm of prostate cancer diagnosis. Randomized studies have demonstrated a diagnostic benefit of clinical significance for targeted biopsy compared to standard systematic biopsies. We evaluated whether multiparametric magnetic resonance imaging informed targeted biopsy has superior diagnosis rates of any, clinically significant, high grade and clinically insignificant prostate cancer compared to systematic biopsy in biopsy naïve men. MATERIALS AND METHODS: Data were searched in Medline®, Embase®, Web of Science and Evidence-Based Medicine Reviews-Cochrane Database of Systematic Reviews from database inception until 2019. Studies were selected by 2 authors independently, with disagreements resolved by consensus with a third author. Overall 1,951 unique references were identified and 100 manuscripts underwent full-text review. Data were pooled using random effects models. The meta-analysis is reported according to the PRISMA statement and the study protocol is registered with PROSPERO (CRD42019128468). RESULTS: Overall 29 studies (13,845 patients) were analyzed. Compared to systematic biopsy, use of multiparametric magnetic resonance imaging informed targeted biopsy was associated with a 15% higher rate of any prostate cancer diagnosis (95% CI 10-20, p <0.00001). This relationship was not affected by the study methodology (p=0.11). Diagnoses of clinically significant and high grade prostate cancer were more common in the multiparametric magnetic resonance imaging informed targeted biopsy group (risk difference 11%, 95% CI 0-20, p=0.05 and 2%, 95% CI 1-4, p=0.005, respectively) while there was no difference in diagnosis of clinically insignificant prostate cancer (risk difference 0, 95% CI -3 to 3, p=0.96). Notably, the exclusion of systematic biopsy in the multiparametric magnetic resonance imaging informed targeted biopsy arm significantly modified the association between a multiparametric magnetic resonance imaging strategy and lower rates of clinically insignificant prostate cancer diagnosis (p=0.01) without affecting the diagnosis rates of clinically significant or high grade prostate cancer. CONCLUSIONS: Compared to systematic biopsy a multiparametric magnetic resonance imaging informed targeted biopsy strategy results in a significantly higher diagnosis rate of any, clinically significant and high grade prostate cancer. Excluding systematic biopsy from multiparametric magnetic resonance imaging informed targeted biopsy was associated with decreased rates of clinically insignificant prostate cancer diagnosis without affecting diagnosis of clinically significant or high grade prostate cancer.
PURPOSE: Multiparametric magnetic resonance imaging with informed targeted biopsies has changed the paradigm of prostate cancer diagnosis. Randomized studies have demonstrated a diagnostic benefit of clinical significance for targeted biopsy compared to standard systematic biopsies. We evaluated whether multiparametric magnetic resonance imaging informed targeted biopsy has superior diagnosis rates of any, clinically significant, high grade and clinically insignificant prostate cancer compared to systematic biopsy in biopsy naïve men. MATERIALS AND METHODS: Data were searched in Medline®, Embase®, Web of Science and Evidence-Based Medicine Reviews-Cochrane Database of Systematic Reviews from database inception until 2019. Studies were selected by 2 authors independently, with disagreements resolved by consensus with a third author. Overall 1,951 unique references were identified and 100 manuscripts underwent full-text review. Data were pooled using random effects models. The meta-analysis is reported according to the PRISMA statement and the study protocol is registered with PROSPERO (CRD42019128468). RESULTS: Overall 29 studies (13,845 patients) were analyzed. Compared to systematic biopsy, use of multiparametric magnetic resonance imaging informed targeted biopsy was associated with a 15% higher rate of any prostate cancer diagnosis (95% CI 10-20, p <0.00001). This relationship was not affected by the study methodology (p=0.11). Diagnoses of clinically significant and high grade prostate cancer were more common in the multiparametric magnetic resonance imaging informed targeted biopsy group (risk difference 11%, 95% CI 0-20, p=0.05 and 2%, 95% CI 1-4, p=0.005, respectively) while there was no difference in diagnosis of clinically insignificant prostate cancer (risk difference 0, 95% CI -3 to 3, p=0.96). Notably, the exclusion of systematic biopsy in the multiparametric magnetic resonance imaging informed targeted biopsy arm significantly modified the association between a multiparametric magnetic resonance imaging strategy and lower rates of clinically insignificant prostate cancer diagnosis (p=0.01) without affecting the diagnosis rates of clinically significant or high grade prostate cancer. CONCLUSIONS: Compared to systematic biopsy a multiparametric magnetic resonance imaging informed targeted biopsy strategy results in a significantly higher diagnosis rate of any, clinically significant and high grade prostate cancer. Excluding systematic biopsy from multiparametric magnetic resonance imaging informed targeted biopsy was associated with decreased rates of clinically insignificant prostate cancer diagnosis without affecting diagnosis of clinically significant or high grade prostate cancer.
Entities:
Keywords:
biopsy; multiparametric magnetic resonance imaging; prostatic neoplasms
Authors: Masatomo Kaneko; Dordaneh Sugano; Amir H Lebastchi; Vinay Duddalwar; Jamal Nabhani; Christopher Haiman; Inderbir S Gill; Giovanni E Cacciamani; Andre Luis Abreu Journal: Curr Urol Rep Date: 2021-03-22 Impact factor: 3.092
Authors: Anwar R Padhani; Ivo G Schoots; Baris Turkbey; Gianluca Giannarini; Jelle O Barentsz Journal: Eur Radiol Date: 2020-11-25 Impact factor: 5.315
Authors: Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena Journal: Nat Rev Urol Date: 2021-10-19 Impact factor: 14.432
Authors: Jakob Schlegel; Stefan Hinz; Karsten Günzel; Ahmed Magheli; Jonas Busch; Eduard Baco; Hannes Cash; Stefan Heinrich; Daniela Edler; Martin Schostak; Hendrik Borgmann Journal: Int Urol Nephrol Date: 2022-07-25 Impact factor: 2.266
Authors: Andreas G Wibmer; Joshua Chaim; Yulia Lakhman; Robert A Lefkowitz; Josip Nincevic; Ines Nikolovski; Evis Sala; Mithat Gonen; Sigrid V Carlsson; Samson W Fine; Michael J Zelefsky; Peter Scardino; Hedvig Hricak; Hebert Alberto Vargas Journal: J Urol Date: 2020-11-18 Impact factor: 7.450
Authors: Bas Israël; Jos Immerzeel; Marloes van der Leest; Gerjon Hannink; Patrik Zámecnik; Joyce Bomers; Ivo G Schoots; Jean-Paul van Basten; Frans Debruyne; Inge van Oort; Michiel Sedelaar; Jelle Barentsz Journal: BJU Int Date: 2021-08-23 Impact factor: 5.969